A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Official Title

Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Summary:

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer (PC) and to use the variants reported to assess biomarker eligibility for niraparib interventional studies.

Trial Description

Primary Outcome:

  • Percentage of Participants with 4 or more DNA-repair Defects with Metastatic Prostate Cancer as an Estimate for Prevalence
  • Percentage of Participants who Meet Biomarker Eligibility Criteria for Other Niraparib Interventional Studies
Secondary Outcome:
  • Percentage of Participants with 4 or more DNA-repair defects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and with Metastatic Hormone Sensitive PC (HSPC) as an Estimate for Prevalence
  • Percentage of Participants with 1 or more DNA-repair defects with Metastatic Prostate Cancer as an Estimate for Prevalence

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society